5 emerging biotech IT firms to watch

It's been about four months since FierceBiotechIT highlighted 5 emerging companies in the eClinical field. Since then, we've talked to many more interesting providers of software for the life sciences market. Some of them have been covered in these pages while others have been flying under the radar.

This report gives FierceBiotechIT a chance to feature 5 software groups that are addressing a range of different needs for biotechs and other life sciences companies. Here you'll find a Silicon Valley startup taking on big competitors with new technology for integrating data from disparate sources and providing developers with insights about their clinical trials. There's a Boston-area company using advanced analytics to spot biomarkers and other tantalizing details about health with the aid of supercomputing technology. And another group based in the U.K. has been quietly growing with R&D software originally licensed from Merck.

These are largely emerging companies whose businesses could take off and grow exponentially in the coming years. The companies could also flop, as they face the risks inherent in introducing novel technology to an industry. FierceBiotechIT is picking them to be winners, however, because all of them are tackling different business challenges that life sciences companies face--including a need to draw meaning from huge amounts of phenotypic and genotypic data to advance drug R&D, how to gain visibility into the minute details of ongoing clinical trials to catch mistakes or make studies run efficiently, and giving scientists the IT tools that enable them to visualize chemical data and manage experiments.

  • Cambridge Semantics
  • Comprehend Clinical
  • GNS Healthcare
  • NextDocs
  • Dotmatics
Read more on

Suggested Articles

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

Elligo Health Research will test a harmonized real-word data model built by the FDA.

Just about a year after filing its IPO application BGI hits a big wall with a regulatory review.